Molecular Partners Expands Radio-DARPin Flexibility with Multi-Isotope Preclinical Data
Event summary
- Molecular Partners presented preclinical data at the 3rd Global Radiopharmaceuticals Development Summit on March 19, 2026, showing Radio-DARPins' compatibility with multiple isotopes.
- Studies in tumor-bearing mice demonstrated comparable biodistribution profiles for Radio-DARPins labeled with Lutetium-177 (177Lu) or Lead-203 (203Pb).
- MP0712, a DLL3-targeted 212Pb-based Radio-DARPin, is in an ongoing Phase 1/2a trial in the US (NCT07278479).
- Molecular Partners entered an agreement with Eckert & Ziegler in February 2026 for development and manufacturing support of Radio-DARPin therapeutics.
The big picture
Molecular Partners' latest preclinical data underscores the strategic advantage of its Radio-DARPin platform, which allows for isotope interchangeability without restarting the drug discovery process. This flexibility is critical in the competitive radiopharmaceutical space, where targeted alpha therapy is gaining traction for treating cancers like small cell lung cancer. The company's partnerships with industry specialists further strengthen its position as it navigates the complex landscape of isotope development and manufacturing.
What we're watching
- Pipeline Flexibility
- How Molecular Partners' ability to switch isotopes late in development will impact the speed and cost of bringing Radio-DARPin candidates to market.
- Clinical Validation
- Whether the preclinical data on biodistribution profiles will translate into clinical success for MP0712 and other Radio-DARPin candidates.
- Strategic Partnerships
- The pace at which Molecular Partners can leverage its partnerships with Orano Med and Eckert & Ziegler to advance its radiopharmaceutical pipeline.
Related topics